Physician profile
Ronald Jefferson
NPI 1730389800
$45,119.87
in general payments reported to CMS, 2019-2025
15 companies · $817 in 2025
The $817 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,702 · 2021: $3,948 · 2022: $4,217 · 2023: $9,675 · 2024: $11K · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $4,006 · Travel and Lodging: $1,610 · Education: $28.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,060.00 |
| Food and Beverage | $4,005.76 |
| Travel and Lodging | $1,610.30 |
| Education | $28.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41,074.38 | 2019-2025 | Biktarvy, Vemlidy, Epclusa |
| Viiv Healthcare Company | $2,246.14 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $566.47 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Janssen Biotech, INC. | $427.66 | 2019-2023 | Symtuza |
| Abbvie INC. | $193.61 | 2019 | |
| Theratechnologies INC. | $169.53 | 2019 | |
| Napo Pharmaceuticals INC | $168.87 | 2019-2024 | Mytesi |
| Emd Serono, INC. | $89.19 | 2019-2021 | |
| Janssen Products, LP | $68.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2023 | |
| Pfizer INC. | $21.98 | 2022 | |
| Alkermes, INC. | $20.58 | 2019 | |
| Dynavax Technologies Corporation | $16.59 | 2022 | |
| Melinta Therapeutics, LLC | $15.66 | 2019 | |
| Organon LLC | $11.78 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Jefferson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.